Online citations, reference lists, and bibliographies.
← Back to Search

Trimodality Treatment In Malignant Pleural Mesothelioma: An Ordeal Or The Real Deal?

N. Mummudi, A. Khan, A. Tibdewal, R. Kumar, S. Jiwnani, G. Karimundackal, P. S. C, J. Agarwal
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND: Malignant Pleural Mesothelioma is an uncommon and aggressive disease associated with asbestos exposure. Management of MPM is complex and controversial as there is paucity of good quality evidence. Multimodality treatment with surgery, systemic therapy and radiation therapy is an option in non-metastatic MPM. We intend to analyze toxicity and outcomes in patients who received trimodality treatment for non-metastatic MPM at our institution. METHODS and MATERIALS: We reviewed the electronic medical records of surgically managed MPM patients at our institution in the last decade. Patient details, disease characteristics and treatment information were retrieved from the institutional electronic medical record and radiation oncology information system. Dosimetric parameters of target volume and organs at risk were documented from Eclipse workstation (v13.6, Varian medical systems). SPSS was used for statistical analysis. RESULTS: Between January 2008 and October 2018, 21 patients (17 male and 4 female) underwent surgery for MPM, all but 2 patients underwent extra-pleural pneumonectomy (EPP). Primary was located in the right and left in 11 and 10 patients respectively. Epithelioid MPM was the commonest histology (17 patients: 81%). Resection was R0 in 18 patients and R2 in 2 patients. Four patients had minor complications like wound erythema, wound seroma with cellulitis and hypotension and 8 Patients had major complications like pneumonia, rib fracture, pulmonary hypertension and pulmonary stump thrombus. All patients received neoadjuvant Pemetrexed/platinum doublet chemotherapy, except for 2. Fourteen patients received adjuvant hemithoracic RT; of these, 2 underwent treatment elsewhere and 2 were treated with conventional technique. Ten patients treated with conformal technique at our institute and dosimetric data was available for analysis. Average time to start RT after surgery was 51 days (range 32 to 82 days). All patients were treated with conformal technique using IMRT/VMAT to a dose of 45Gy in 25 fractions; one patient received a further boost of 5.4Gy. Mean overall RT duration was 35 days (range 30 to 42 days). Acute toxicity was uncommon; Grade I/II Pneumonitis was seen in 4 patients. One patient developed grade III acute lung toxicity unrelated to RT. At a median follow up of 25 months, 8 patients developed progressive disease. Eight patients had died, of whom six died due to disease and two died in immediate post op period. Two-year DFS and OS were 58% and 73% respectively. CONCLUSION: In spite of the extensive surgery and complex hemithoracic RT, we demonstrated excellent dosimetric, toxicity profile and favorable outcomes in non-metastatic MPM.
This paper references
10.2147/LCTT.S83338
Modern management of malignant pleural mesothelioma
S. Patel (2016)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1258/jrsm.2010.100345
A systematic review of lung-sparing extirpative surgery for pleural mesothelioma
Elaine S Teh (2011)
10.1200/JCO.2017.73.8401
Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.
D. Nelson (2017)
Second- or thirdline nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A Scherpereel (2017)
10.1016/j.lungcan.2013.11.026
A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma.
C. Cao (2014)
10.1200/JCO.2017.35.18_SUPPL.LBA8507
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A. Scherpereel (2017)
10.21037/jtd.2018.07.65
Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.
G. Cramer (2018)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
A systematic review and metaanalysis of surgical treatments for malignant pleural mesothelioma
C Cao (2014)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1093/jrr/rru102
Clinical experience of volumetric modulated arc therapy for malignant pleural mesothelioma after extrapleural pneumonectomy
T. Kimura (2015)
10.1097/MCP.0000000000000489
Updates in the diagnosis and treatment of malignant pleural mesothelioma
D. Katzman (2018)
Gy) 472.28 PTV Volume (cc)
Dmean
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1097/JTO.0b013e3181b9eb85
Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques
C. Hill-Kayser (2009)
10.1371/journal.pone.0145039
Determinants of Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) Study of 14,228 Patients
E. Taioli (2015)
10.1016/j.radonc.2019.05.024
Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial.
O. Riesterer (2019)
10.1016/j.athoracsur.2017.09.036
National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study.
Sahar A Saddoughi (2018)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.3857/roj.2019.00150
Preliminary results of entire pleural intensity-modulated radiotherapy in a neoadjuvant setting for resectable malignant mesothelioma
J. H. Hong (2019)
10.4103/0973-1482.187284
Evaluation of the photon dose calculation accuracy in radiation therapy of malignant pleural mesothelioma
G. Mahmoudi (2018)
10.1200/JCO.2016.67.2675
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner (2016)
10.1016/S1470-2045(16)30095-X
Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial
A. Clive (2016)
10.1016/J.IJROBP.2007.07.2370
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
J. Krayenbuehl (2007)
10.1016/j.ijrobp.2008.05.024
Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers.
D. Gomez (2009)
10.1016/S1470-2045(15)00208-9
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
R. Stahel (2015)



Semantic Scholar Logo Some data provided by SemanticScholar